
Insmed Incorporated INSM
€ 117.54
-5.56%
Geschäftsbericht 2025
hinzugefügt 19.02.2026
Insmed Incorporated Langfristige Verbindlichkeiten 2011-2026 | INSM
Langfristige Verbindlichkeiten Jährlich Insmed Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 395 M | 317 M | 56.3 M | 55.5 M | 22.6 M | 25 M | 16.7 M | 16.9 M | 1.09 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 395 M | 1.09 M | 101 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Benitec Biopharma
BNTC
|
213 K | $ 10.98 | -4.52 % | $ 452 M | ||
|
Ascendis Pharma A/S
ASND
|
101 M | $ 221.88 | -0.87 % | $ 5 B | ||
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Milestone Pharmaceuticals
MIST
|
696 K | $ 1.36 | -20.0 % | $ 45.5 M | ||
|
Pharming Group N.V.
PHAR
|
21.6 M | $ 15.36 | -0.71 % | $ 7.59 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Inventiva S.A.
IVA
|
13.8 M | $ 5.78 | -4.3 % | $ 138 M | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
290 K | $ 1.21 | -3.97 % | $ 71.5 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
PainReform Ltd.
PRFX
|
259 K | $ 2.28 | -0.44 % | $ 1.03 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Assembly Biosciences
ASMB
|
18.2 M | $ 28.46 | 3.45 % | $ 319 M | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.37 | -4.2 % | $ 350 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Axsome Therapeutics
AXSM
|
48.9 M | $ 156.92 | -1.23 % | $ 7.81 B | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
AbCellera Biologics
ABCL
|
326 M | $ 3.4 | -3.68 % | $ 1.02 B | ||
|
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
BioMarin Pharmaceutical
BMRN
|
635 M | $ 54.13 | -1.64 % | $ 10.4 B | ||
|
Calithera Biosciences
CALA
|
4.82 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | ||
|
Compugen Ltd.
CGEN
|
31.3 M | $ 2.09 | -0.95 % | $ 195 M | ||
|
Coherus BioSciences
CHRS
|
189 M | $ 1.52 | -5.59 % | $ 178 M | ||
|
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
579 M | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
25.1 M | $ 8.6 | -3.8 % | $ 115 M | ||
|
Curis
CRIS
|
62.5 M | $ 0.77 | 1.89 % | $ 4.86 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B |